ARA-290 (cibinetide) research peptide for laboratory investigation of innate repair receptor signalling and tissue-response models.
For laboratory research only. Not for human or veterinary use. This page is scientific background, not medical advice or a treatment claim.
Product overview
Product typeResearch peptide
Research focusInnate repair receptor and small-fibre models
FormLyophilised material in a vial
Research context
ARA-290, also called cibinetide, is an erythropoietin-derived peptide designed to study tissue-protective signalling without erythropoietic activity. Small controlled human trials explored neuropathy-related symptoms and corneal nerve measures in defined patient populations. Those findings are not evidence that this separately supplied vial has the same identity or clinical suitability.
See the Research tab for linked publications and their evidence limits.
Batch documentation
Review available lot-matched analytical documentation on our batch testing page. A publication or test from another lot does not authenticate this vial.
Supply and laboratory handling
- Confirm the selected option, vial label and lot documentation on receipt.
- Keep sealed and protected from light and moisture; follow validated laboratory storage procedures.
- Record handling and follow applicable laboratory safety protocols.
Frequently asked questions
What is ARA-290?
ARA-290 is an engineered erythropoietin-derived peptide investigated as an innate repair receptor agonist.
What has been studied?
Published controlled studies examined exploratory neuropathy and small-nerve-fibre endpoints in selected groups; they are not product performance claims.
Are trial findings a quality certificate?
No. Only lot-matched analytical information can help establish the identity and characteristics of this vial.
Information reviewed: 28 September 2026.
Batch-specific analytical documentation
Independent analytical results are published for selected Havoc Labs products, vial sizes and batches. The result attached to one variation must not be treated as evidence for a different size or batch.
- Result available: a published report is available for the marked variation.
- Test pending: a sample has been submitted, but no completed result is being claimed.
- No indicator: no product-specific result is currently displayed for that variation.
Check the identifiers
Always match the compound, vial size and batch reference on the product to the corresponding laboratory record. Where the laboratory provides an independent verification facility, use it to confirm the report.
Browse published lab results →
Storage and stability
Storage requirements can vary by compound, physical form, intended storage duration and batch. Follow the lot-specific documentation and your laboratory’s validated procedure wherever these are available.
| Form |
Suggested storage |
Important note |
| Sealed lyophilised material |
Keep in a cool, dry place, refrigerated at 2–8°C or frozen, as appropriate for the compound and intended storage period. |
Keep sealed, dry and protected from direct light. Follow compound- and batch-specific documentation and avoid repeated temperature cycling. |
| Reconstituted solution |
Refrigerate at 2–8°C unless the applicable laboratory protocol specifies otherwise. |
Stability depends on the preparation conditions, solvent, concentration, container and handling. No universal storage period is claimed. |
No universal shelf-life is claimed
Do not assume a fixed expiry or prepared-solution storage period unless it is supported by relevant stability data or batch documentation. Where a lot-specific document gives different instructions, that document takes precedence.
Published research
ARA-290 (cibinetide) has been examined in exploratory controlled human studies of small-fibre neuropathy and innate repair receptor signalling. Trial preparations and patient groups differ from this research vial.
- Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study. Molecular Medicine, 2012. Exploratory placebo-controlled study in 22 patients; assessed symptoms and safety over a short follow-up. View on PubMed ↗
- ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density. Molecular Medicine, 2013. Blinded placebo-controlled study examining symptom and corneal-nerve endpoints. View on PubMed ↗
- Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain. Investigative Ophthalmology and Visual Science, 2017. Phase 2b randomised study in 64 participants assessing surrogate nerve-fibre measures and clinical endpoints. View on PubMed ↗
Research endpoints are not product claims. Small trials and surrogate endpoints do not establish broad clinical efficacy or long-term safety. Published material does not verify the identity, purity or suitability of this batch. Confirm identity and purity against lot-matched analytical documentation. Research use only; not for human or veterinary use.
References reviewed 28 September 2026.
